Biocon

Delivering Affordable Innovation

[Biocon @Bioconlimited]

Innovation changes healthcare.​
Access changes lives.​

See how biosimilars are helping expand access to advanced cancer care in #RewritingCancer, presented by @UICC and produced by @BBCStoryWorks.​

Watch now: https://t.co/8qsD9sPvmv

#Biocon #CancerCare #Oncology #Biosimilars #AccessToCare #PatientImpact

Disclaimer: This content is for educational purposes only and is not medical advice. Consult a healthcare professional for treatment decisions. The experiences described are individual and may not be representative of all patients.

[Biocon @Bioconlimited]

For more than a decade, Biocon has worked to help make advanced therapies more accessible and affordable to patients worldwide.​

At the heart of our episode in #RewritingCancer, presented by @UICC and produced by @BBCStoryWorks, is one patient's story of hope and resilience.​

Through her journey, we see how purpose-led science has transformed cancer care, how biosimilars are helping expand access to treatment, and why innovation can only make a difference when it reaches the people who need it.​

Part of the #RewritingCancer series, the film joins stories from around the world that show how progress is changing what is possible for patients everywhere.

Watch the film now: https://t.co/frZMRgsZNg

#RewritingCancer #Biocon #oncology #cancer #cancercare #biosimilars

[Biocon @Bioconlimited]

A bold bet. A long journey.​
And the belief that advanced therapies should be affordable and accessible to everyone.

Our story in #RewritingCancer, presented by @uicc and produced by @BBCStoryWorks, explores why that idea continues to matter in cancer care today.​

Stay tuned.

#Biocon #CancerCare #ScienceForLife #AccessToCare #PatientImpact

Disclaimer: The experiences described are individual and may not be representative of all patients

[Biocon @Bioconlimited]

Cancer care has come a long way.​

What we've learned about the disease is helping change how it's treated.​
And scientific advances like biosimilars are helping expand access to treatment.​
Stay tuned.​

#RewritingCancer #Biocon #Biosimilars #CancerCare #Oncology​

Disclaimer: The experiences described are individual and may not be representative of all patients.

[Biocon @Bioconlimited]

As Prime Minister @narendramodi completes a decade in office, @kiranshaw, Founder & Chairperson, #Biocon, reflects on the #leadership journey that has sought to reshape India’s development trajectory and redefine its place in the world.

“Scientific capability is not merely an academic pursuit. It is a strategic national asset. It underpins economic competitiveness, technological sovereignty, healthcare security, energy resilience and long-term national prosperity.” @PMOIndia @MIB_India

[Biocon @Bioconlimited]

Twenty years ago, Europe changed the course of global healthcare by approving the world’s first biosimilar medicine. Since 2006, biosimilars have proven to be a vital tool in supporting healthcare systems’ resilience, while offering more treatment options for chronic and high-impact diseases. 

Over the past two decades, biosimilars have supported nearly 7 billion days of treatment for patients and generated €56 billion in cumulative savings across Europe.* 

But the need ahead is even greater. 

As the burden of chronic disease continues to rise, placing increasing pressure on healthcare budgets, and more biologic medicines approach patent expiry, the role of biosimilars in helping the healthcare system and expanding patient access will only grow. 

At Biocon, we are driven by this mission. Biosimilars remain a fundamental and invaluable asset for patient care, healthcare system resilience, and broader access to life-changing treatments. 

Let’s continue building this journey together.   

#Biocon #Biosimilars 

*Medicines For Europe: https://t.co/47tNbkX6Vu

[Biocon @Bioconlimited]

This World Environment Day, we reflect on the actions helping shape a more sustainable future, at Biocon.

We have reused and recycled over 90% of waste and achieved 73% renewable energy adoption through green energy partnerships. Through our responsible operations and a sustainable corporate commute program, we have avoided nearly 193,337 tons of CO₂ emissions, while also supporting community-led initiatives such as tree plantation drives and lake rejuvenation projects.​
​
Our continued focus on sustainable practices has translated into external recognition across leading global sustainability and industry platforms. Biocon secured 17th position among BW India’s Top 60 Most Sustainable Companies 2025 and has been included in the S&P Global Sustainability Yearbook for the fourth consecutive year, alongside winning the Excellence in ESG Award at the ET Re Pharma Awards 2026. Our manufacturing sites have also been recognized for excellence in EHS and industrial safety practices. ​
​
These outcomes are guided by a clear purpose: responsible innovation is shaped not only by science, but also by how we operate, collaborate and champion sustainable practices to create long-term global impact. ​

Image credit (slide 5): The Hindu (June 4, 2026)
#Biocon #WorldEnvironmentDay #Sustainability #ESG #Biotechnology #ClimateAction #Volunteering #Recycling #CarbonFootprint

[Biocon @Bioconlimited]

Melanoma is one of the most serious forms of skin cancers, with global cases projected to rise by more than 50% by 2040 according to a study published in JAMA Dermatology.​

However, the Skin Cancer Foundation states melanoma is highly treatable when detected early, with survival rates exceeding 90% in many early-stage cases. Advances in treatment are also improving outcomes for many patients.​

Melanoma can begin with subtle changes in the skin. Dermatologists recommend paying attention to the ABCDE signs of melanoma: asymmetry, irregular borders, uneven colour, diameter larger than 6 mm, or an evolving shape or size, itching or bleeding. ​

These signs can help support earlier detection and timely medical attention.​

Listen to your skin. Notice the changes. Early awareness can help ensure better outcomes. ​

Sources:
JAMA Dermatology: https://t.co/KJf1JQKibT
American Academy of Dermatology Association: https://t.co/gT3zSHoeM3
Skin Cancer Foundation: https://t.co/vShZD6jvTj

#MelanomaAwarenessMonth #SkinCancer #Melanoma #SkinHealth #Biocon #ListenToYourSkin

[Biocon @Bioconlimited]

Persistent abdominal discomfort is often overlooked, yet for many people it may signal a chronic inflammatory bowel disease (IBD).​

On World Inflammatory Bowel Disease Day, we recognize the importance of greater awareness, earlier diagnosis, and timely care for conditions such as Crohn’s disease and ulcerative colitis.​

​As IBD is increasingly becoming a global concern, expanding access to affordable therapies remains essential to improving long-term outcomes for patients.​

​At Biocon, we are committed to working with healthcare communities to help make this possible.​

#WorldIBDDay #IBD #Gastroenterology #Biocon #Biosimilars #Generics #Healthcare #Immunology #Healthcare

[Biocon @Bioconlimited]

At the Panhellenic Conference on Inflammatory Bowel Diseases (IBD) in Rhodes, Biocon Greece engaged with gastroenterology experts on the evolving future of IBD care.​

Between 2018 and 2022, the proportion of Greek IBD patients using biosimilars increased from 33% to 67%, reflecting the growing role of biosimilars in improving healthcare sustainability and access to care.​

​As the burden of chronic autoimmune diseases continues to rise, expanding access to sustainable, long-term IBD care is more essential than ever before. ​

​Our teams discussed treatment optimization, disease management strategies, and the critical role biosimilars can play in supporting both healthcare systems and patients across Greece.​

​At Biocon, we are committed to advancing access to affordable therapies and improving long-term outcomes for people living with IBD.​

​#Biocon #IBD #Biosimilars #Healthcare #Immunology #Gastroenterology​

​Source: https://t.co/NzTXtbycUQ

[Biocon @Bioconlimited]

In the May cover story of @FortuneIndia, @kiranshaw reflects on over four decades of building Biocon — from pioneering industrial enzymes to becoming a global biosimilars leader. A journey defined by reinvention, innovation, and the courage to take bold bets where others saw uncertainty. ​

As Biocon looks ahead to its next chapter, the focus is clear: high-value biotech innovation, powered by emerging technologies such as AI. ​

In the same feature, Shreehas Tambe outlines the three strategic priorities shaping Biocon’s next phase of growth: integrating technology platforms to unlock scale and efficiency, embedding augmented intelligence – AI amplified by human intelligence – to accelerate innovation and enable smarter decision-making, and transforming Biocon into a stronger global market-facing organisation. ​

With the launch of Office of Augmented Intelligence and enterprise-wide investments in data digitisation, Biocon is building an ecosystem where human expertise and AI work together to unlock new possibilities in biotech innovation. ​

As Kiran Mazumdar-Shaw and Shreehas Tambe share in the story, the future of biotech will belong to those who can combine scientific ambition with technological intelligence.

#Biocon #Biosimilars #AIinHealthcare #AugmentedIntelligence #BiotechInnovation #KiranShaw #Biotech #India

[Biocon @Bioconlimited]

“FY26 was a pivotal year for Biocon, marked by the successful integration of our biosimilars and generics business to create one unified biopharmaceutical enterprise with greater scale, capability, and reach. Even as we integrated the businesses, Biocon delivered ~200 basis points of EBITDA margin expansion at a consolidated level on a like-to-like basis, driven by an improved product mix and operational excellence.

Our biosimilars business recorded 16% YoY growth in revenue and 40% increase in EBITDA, on a like-to-like basis. Growth was led by strong performance in advanced markets and key tender wins across emerging markets. With the integration now complete, we shift gears in fiscal 2027 from the “Preserve�� phase of our strategy to “Consolidate”, as we set up the business for sustainable growth.”

– Shreehas Tambe, CEO and Managing Director, Biocon Limited

#FY26results #Q4FY26

Read more: https://t.co/uyzaq5Khj7

[Biocon @Bioconlimited]

Biocon closed #FY26 on a strong note despite a complex geopolitical environment. This performance reflects the resilience of our business and disciplined execution through a pivotal year of integration of our biosimilars and generics business to create one unified biopharma enterprise with greater scale, capability, and reach.

Q4 highlights:

•Operating Revenue at Rs. 4,517 crore, up 10% year-on-year (YoY), after adjusting for one-time generic Lenalidomide sales in Q4FY25.

•EBITDA at Rs. 1,073 crore. Adjusted for generic Lenalidomide sales, EBITDA was up 29% YoY, with a margin of 23%.

•Net Profit (before exceptional items) is Rs. 179 crore.

FY26 highlights:

•Operating Revenue at Rs. 16,927 crore, up 13% year-on-year (YoY), after adjusting for one-time generic Lenalidomide sales in FY25.

•EBITDA at Rs. 3,798 crore. Adjusted for generic Lenalidomide sales and for BFI divestment gain, EBITDA was up 25% YoY.

•EBITDA margin at 22%, up 200 basis points, on a like-to-like basis.

•Net Profit (before exceptional items) is Rs. 436 crore.

Read more: https://t.co/uyzaq5Khj7

#FY26Results #Q4FY26

[Biocon @Bioconlimited]

"Biocon closed FY26 on a strong note despite a complex geopolitical environment. We delivered margin expansion along with 13% YoY growth in operating revenue, excluding the one-time impact of generic lenalidomide sales last year. This performance reflects the resilience of our business and disciplined execution through a pivotal year of integration.

We have created a unified biopharma entity by integrating biosimilars business with generics formulations and APIs business. The combined business has a stronger balance sheet, improved leverage metrics and a more global commercial footprint. We are now focused on profitability enhancement and long-term value creation.”

– @kiranshaw, Executive Chairperson, Biocon Limited

#FY26results #Q4FY26

Read more: https://t.co/mWoWNm5YvJ

[Biocon @Bioconlimited]

@kiranshaw, Executive Chairperson, Biocon, is among the women featured in Her Place Women's Museum’s ‘Finding Her’ - an Australian initiative that documents women whose contributions are commemorated through places, streets and landmarks in Australia.​

What makes this initiative distinctive is its use of geographical tagging to map these recognitions, creating a digital archive that connects stories, spaces and history in a powerful, accessible way.​

The feature highlights Mazumdar-Shaw Drive at Federation University Australia's Mt. Helen campus in Victoria, Australia, unveiled in2015, a lasting tribute that reflects her global impact beyond industry, shaped by purpose-driven science and a commitment to advancing affordable innovation in global health.​

By documenting how women are remembered in public spaces, ‘Finding Her’ is building a visible record of leadership, legacy and progress – echoing the broader impact of science-led innovation in shaping societies.​

Read more here: https://t.co/gPBNDuMJzr

#Biocon #KiranMazumdarShaw #WomenInLeadership

[Biocon @Bioconlimited]

@kiranshaw, Executive Chairperson, Biocon Limited, has been honored as a SAHIT Global Icon 2025, recognizing her contributions to biotechnology, entrepreneurship and advancing affordable healthcare in India.​

SAHIT is a platform convening changemakers across sectors to shape a strategic roadmap for Viksit Bharat 2047, with a special focus on advancing women's participation and leadership in the workforce.​

#Biocon #ViksitBharat #WomenInLeadership #SAHIT

[Subi Chaturvedi @subichaturvedi]

Honouring 𝗠𝘀. 𝗞𝗶𝗿𝗮𝗻 𝗠𝗮𝘇𝘂𝗺𝗱𝗮𝗿-𝗦𝗵𝗮𝘄 𝗮𝘀 𝗮 𝗦𝗔𝗛𝗜𝗧 Global 𝗜𝗖𝗢𝗡 𝟮𝟬𝟮𝟰-𝟮𝟱

Two years ago, we started Sahit with one ambition: create a platform that facilitates equality, equity and inclusion.
Supported by Indian National Science Academy - INSA @insa_academy , Miranda House, @UnivofDelhi and ASSOCHAM, our first goal: getting more women in the formal workforce. This is crucial to competing with large global economies and achieving ambitious growth targets. We need female heroes and role models to drive systemic change, challenge structural barriers, inspire the next generation, and redefine what leadership looks like in India. That is why we celebrate women leaders, achievers and changemakers who are not just breaking barriers, but building pathways, reshaping systems, and paving the way for the next generation.

It gives me immense pleasure to recognize Dr. Kiran Mazumdar Shaw (@kiranshaw) as a 𝗦𝗔𝗛𝗜𝗧 Global 𝗜𝗖𝗢𝗡 𝟮𝟬𝟮𝟱 for her extraordinary leadership, pioneering spirit, and transformative impact as a trailblazing entrepreneur in India’s biotechnology sector. As the Founder and Executive Chairperson of @Bioconlimited, she has not only built a globally respected enterprise but also redefined the role of Indian innovation in advancing affordable healthcare solutions.

She has created thousands of jobs, nurtured countless startups, and put Bengaluru on the global biotech map. Her leadership extends far beyond the boardroom, through the Mazumdar Shaw Medical Foundation, she’s made world-class cancer care accessible to all, embodying the spirit of seva (service) alongside enterprise.

As a fearless pathbreaker, she didn't just build a company; she built an industry. When the world said India couldn't manufacture complex biologics, she pioneered the country's first indigenous insulin and slashed cancer drug prices by over 90%. In doing so, she transformed India from a dependent consumer into a global hub for affordable, life-saving healthcare, proving that commercial success and social impact are not opposites but allies.

A vocal advocate for women in #STEM, she has consistently used her platform to mentor the next generation of female scientists and entrepreneurs, urging them to “think big, fail fast, and never settle.”

@Sahit_Platform honours Ms. Shaw not just as a nation-builder who seamlessly blends profit with purpose, innovation with inclusion, and ambition with empathy. Her unparalleled contribution to India’s biotech sovereignty, unwavering commitment to affordable healthcare, and her role as a torchbearer for women-led development, we proudly confer upon her the SAHIT Global Icon Award.

She was formally recognized on the 27th March, 2026, by @DrJitendraSingh, Union Minister of State (Independant charge) Department of Science & Technology, Government of India (@IndiaDST) and Earth Sciences & me at the SAHIT Summit & Awards, Delhi.

Many congratulations Dr Kiran Mazumdar Shaw, and thank you for inspiring an entire generation.

@ASSOCHAM4India @able_indiabio @ITBTGoK

#SAHIT #SAHIT2025 #innovation #publicpolicy #biotech

[Biocon @Bioconlimited]

Bengaluru just got a new soul — and you can see it the moment you land.

At the Arrival Forecourt of Terminal 2, Kempegowda International Airport Bengaluru, “Bengaluru’s Soul,” a striking new cultural landmark by critically acclaimed Spanish artist Jaume Plensa, now welcomes the world.

The installation was unveiled by H.E. Juan Antonio March Pujol, Ambassador of Spain to India, in the esteemed presence of Mr. Priyank M Kharge, Honourable Minister for Rural Development, Panchayat Raj, and Information Technology & Biotechnology, Government of Karnataka, with @kiranshaw, Chairperson, Biocon Group, and @HariMarar, Managing Director & CEO, Bangalore International Airport Limited (BIAL), in attendance, alongside artist Jaume Plensa.

More than an installation, it is a statement—a reflection of a city that has evolved beyond its identity as India’s tech capital into a global crossroads of culture, ideas and dialogue.

Supported by Biocon Foundation India, the sculpture represents a deeper commitment to Bengaluru’s growth, not just in science and innovation, but in spirit.

From rejuvenating lakes to strengthening urban ecology, advancing public health and enabling community development, the focus remains clear: building a city that is as thoughtful as it is forward-looking.

Because shaping a global city is not just about infrastructure.

It is about nurturing its soul.

@BLRAirport

#Bengaluru #CulturalIdentity #Biocon #UrbanTransformation

[BLR Airport @BLRAirport]

“Bengaluru’s Soul” by renowned artist Jaume Plensa now welcomes arriving passengers at the Arrival Forecourt of Terminal 2, Kempegowda International Airport Bengaluru.

Commissioned by Biocon Foundation in collaboration with Bangalore International Airport Limited, this monumental 16-foot stainless steel sculpture reflects Bengaluru’s layered identity where culture, technology and global exchange converge.

Unveiled on April 25, 2026, by His Excellence Juan Antonio March Pujol (ambassador of Spain to India), Priyank M Kharge (Cabinet Minister, Government of Karnataka), Kiran Mazumdar Shaw (Executive Chairperson and Founder of Biocon Group), Hari Marar (Managing Director and CEO - Bangalore International Airport Ltd) and the artist Jaume Plensa - this installation is the artist's first work in India.

Part of BLR Airport’s evolving Art Programme, the installation weaves art into the passenger journey - creating moments of reflection that shape emotion, movement, and memory.

As BLR Airport rises to the Top 5 in the Skytrax 'World’s Best Art in the Airport 2026', this installation further strengthens our vision as a cultural gateway where art and infrastructure converge.

Artwork: Bengaluru’s Soul
Artist: Jaume Plensa
Material: Painted stainless steel
Dimensions: 500 × 319 × 375 cm
Location: Terminal 2, Arrivals Forecourt, BLR Airport

@EmbEspIndia
@Bioconlimited

#BLRAirport #ArtAtTheHeartOfT2 #Terminal2 #Art #Airport

[Biocon @Bioconlimited]

Sustainability is increasingly shaping how businesses build, scale
and stay relevant.​
​
At Biocon, we embed responsible practices into every layer of our operations, guided by science and focused on long-term impact.​

Ranked 17th among India’s Most Sustainable Companies by @BWBusinessworld India, this recognition underscores Biocon’s belief that sustainability is central to how we build, operate, and grow the business – as a strategic imperative.​
​
This ranking reinforces our focus: advancing science-led innovation while building a business that is resilient, responsible and future- ready.​
​
#Sustainability #ESG #Biocon #IMSC #BWSustainabilityWorld